Expression of cancer-testis antigen in multiple myeloma

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 34, Issue 2, 2014, Pages 181-185

  He, Li ^a   Ji, Jing Na ^a   Liu, Shang Qin ^a   Xue, Er ^a   Liang, Qing ^a   Ma, Zi ^a  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

cancer testis antigen; immunotherapy; multiple myeloma

Indexed keywords

MAGEC1 PROTEIN, HUMAN; REPRESSOR PROTEIN; SYNOVIAL SARCOMA X BREAKPOINT PROTEINS; TUMOR ANTIGEN; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; CANCER STAGING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ADULT; AGED; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM PROTEINS; NEOPLASM STAGING; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84898851806     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-014-1255-7     Document Type: Article

References (24)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med, 2004,351(18):1860-1873
2. Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol, 2012,87(1):78-88
3. Philips S, Menias C, Vikram R, et al. Abdominal manifestations of extraosseous myeloma: cross-sectional imaging spectrum. J Comput Assist Tomogr, 2012,36(2): 207-212
4. Cho HJ, Caballero OL, Gnjatic S, et al. Physical interaction of two cancer-testis antigens, MAGE-C1 (CT7) and NYESO-1 (CT6). Cancer Immun, 2006,6:12
5. Rajagopalan K, Mooney SM, Parekh N, et al. A majority of the cancer/testis antigens are intrinsically disordered proteins. J Cell Biochem, 2011,112(11):3256-3267
6. Caballero OL, Zhao Q, Rimoldi D, et al. Frequent MAGE mutations in human melanoma. PLoS One, 2010,5(9): e12773
7. Curioni-Fontecedro A, Nuber N, Mihic-Probst D, et al. Expression of MAGE-C1/CT7 and MAGE-C2/CT10 predicts lymph node metastasis in melanoma patients. PLoS One, 2011,6(6):e21418.
8. Costa FF, Blanc KL, Brodin B. Concise review: cancer/testis antigens, stem cells, and cancer. Stem Cells, 2007,25(3):707-711
9. Jungbluth AA, Ely S, Diliberto M, et al. The cancer-testis antigens CT7 (MAGEC1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood, 2005,106(1):167-174
10. de Carvalho F, Costa ET, Camargo AA, et al. Targeting MAGE-C1/CT7 expression increases cells sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines. PLoS One, 2011,6(11):e27707
11. Atanackovic D, Hildebrandt Y, Jadczak A, et al. Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells. Haematologica, 2010,95(5):785-793
12. Atanackovic D, Luetkens T, Hildebrandt Y, et al. Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma. Clin Cancer Res, 2009,15(4):1343-1352
13. Smith HA, McNeel DG. The SSX family of cancer-test is antigens as target proteins for tumor therapy. Clin Dev Immunol, 2010,2010:150 591
14. Taylor BJ, Reiman T, Pittman JA, et al. SSX cancer testis antigens are expressed in most multiple myeloma patients: co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCs. J Immunother, 2005,28(6):564-575
15. de Carvalho F, Vettore AL, Colleoni GW. Cancer/testis antigen MAGE-C1/CT7: new target for multiple myeloma therapy. Clin Dev Immunol, 2012,2012:257 695
16. Kim R, Kulkarni P, Hannenhalli S. Derepression of cancer/testis antigens in cancer is associated with distinct patterns of DNA hypomethylation. BMC Cancer, 2013,13:144
17. Hudolin T, Kastelan Z, Ilic I, et al. Immunohistochemical analysis of the expression of MAGE-A and NY-ESO-1 cancer/testis antigens in diffuse large B-cell testicular lymphoma. J Transl Med, 2013,11:123
18. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized bycytolytic T lymphocytes on a human melanoma. Science, 1991,254(5038): 1643-1647
19. de Carvalho F, Alves VL, Braga WM, et al. MAGE-C1/CT7 and MAGE-C2/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy. Cancer Immunol Immunother, 2013,62(1):191-195
20. Atanackovic D, Luetkens T, Hildebrandt Y, et al. Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma. Clin Cancer Res, 2009,15(4):1343-1352
21. Andrade VC, Vettore AL, Felix RS, et al. Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients. Cancer Immun, 2008,8:2
22. Naka N, Joyama S, Tsukamoto Y, et al. Quantification of SSX mRNA expression in human bone and soft tissue tumors using nucleic acid sequence-based amplification. J Mol Diagn, 2005,7(2):187-197
23. Zhang Y, Bao L, Chen H, et al. Expression level of MAGE-C1/CT7 gene in bone marrow cells with multiple myeloma by real-time quantitative PCR. Ch Chin J Clin (Chinese), 2011,5(10):2839-28
24. Akers SN, Odunsi K, Karpf AR. Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy. Future Oncol, 2010,6(5):717-732